Physician profile
Simina Mateescu
NPI 1194539544
$1,952.34
in general payments reported to CMS, 2019-2025
30 companies · $1,952 in 2025
The $1,952 reported for 2025 was more than what 94% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,952.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,952.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,952.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $242.65 | 2025 | Enhertu, Calquence, Imfinzi |
| Incyte Corporation | $157.68 | 2025 | Zynyz, Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $151.66 | 2025 | |
| Janssen Biotech, INC. | $133.26 | 2025 | Darzalex, Tecvayli, Rybrevant |
| Celgene Corporation | $130.67 | 2025 | Reblozyl, Opdualag |
| Daiichi Sankyo INC. | $99.36 | 2025 | Datroway, Enhertu, Injectafer |
| Pfizer INC. | $94.98 | 2025 | |
| Alexion Pharmaceuticals, INC. | $84.18 | 2025 | Ultomiris |
| Regeneron Healthcare Solutions, INC. | $84.10 | 2025 | Libtayo, Lynozyfic |
| Glaxosmithkline, LLC. | $82.90 | 2025 | Ojjaara, Blenrep |
| Lilly USA, LLC | $73.12 | 2025 | Jaypirca, Verzenio |
| Eisai INC. | $65.45 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $64.29 | 2025 | Opdivo |
| Genentech USA, INC. | $59.63 | 2025 | Columvi, Itovebi, Venclexta |
| Array Biopharma INC | $48.68 | 2025 | Lorbrena, Mektovi, Braftovi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tempus Ai, INC | $38.95 | 2025 | Xt Cdx |
| Novocure INC. | $33.42 | 2025 | Optune Lua (Novottf-200t) |
| Legend Biotech USA INC. | $30.16 | 2025 | Carvykti |
| Agios Pharmaceuticals, INC. | $29.51 | 2025 | Pyrukynd |
| Azurity Pharmaceuticals, INC. | $26.83 | 2025 | Danziten |
| Jazz Pharmaceuticals INC. | $26.83 | 2025 | |
| Caris Mpi, INC. | $26.08 | 2025 | Mi Cancer Seek |
| Sobi, INC | $25.77 | 2025 | |
| Geron Corporation | $24.09 | 2025 | Rytelo |
| Pharmacosmos Therapeutics INC. | $22.56 | 2025 | Monoferric |
| Genzyme Corporation | $20.38 | 2025 | |
| Merck Sharp & Dohme LLC | $19.96 | 2025 | Reblozyl, Welireg, Keytruda |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.45 | 2025 | |
| Fennec Pharmaceuticals, INC. | $18.93 | 2025 | Fyarro |
| Puma Biotechnology, INC. | $16.81 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simina Mateescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.